Maintaining proper hydration is key when using GLP-1 medications, and if you notice your feet becoming dry or cracked, its essential to visit your podiatrist for advice on skincare and treatment
Summary: Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, currently in Phase 3 trials for obesity and type 2 diabetes but not yet approved by the MHRA, EMA, or FDA
Rivals are already jockeying for advantage
And it takes a long time for us to burn 50 grams of fat through exercise (80 minutes of jogging, 92 minutes of swimming, 119 minutes of cycling, 64 minutes of jumping rope)
It doesn't appear to work like most pharmaceuticals that latch on to one specific receptor